FDA Commissioner Stephen Hahn sent out a memo Monday (May 11) laying out a process to return to in-person surveillance inspections that have been delayed by the COVID-19 pandemic. FDA plans to phase in onsite inspections following the White House’s guidelines for reopening America and will prioritize the health of both FDA and industry workers. FDA is working with the Centers for Disease Control and Prevention (CDC) to create a process for deciding when and how to return to onsite...